CA19-9免疫放射分析在肿瘤诊断中的应用

Application of CA19-9 IRMA in Cancer Detection

本文介绍了CA19－9免疫放射分析方法的临床应用，其中测定96名正常人血清的平均值为8．32±7．23U／mL，73名结-直肠患者血清（包括DukeA、B、C、D期）的平均值分别为9．68±5．32U／mL、12．87±10．14U／mL、71．11±90．53U／mL、297．55±255．11U／mL。60例胰腺癌血清平均值为196．12±208．30U／mL。若以30U／mL为阳性界值，其结一直肠癌DukeA、B、C、和D期阳性率分别为0％、13．8％、46．7％和87．5％。胰腺癌阳性率为80％。正常人假阳性率为1．04％。本文还应用ROC分析法论证CA19－9IRMA在临床中的应用价值。

Using Mab C192 against glycoprotein antigen CA19-9 as captured antibody and labeled antibody, we have developed a 'sandwich' immunoradiometric assay with a sensitivity of IU/mL. The ratio of standard curve is 34. 2 from 0U/mL to 150U/mL and the intra-assay and inter-assay coefficients of variation are 5. 54% and 10.89%, respectively. In 96 serum samples form healthy subjects, the mean concentrafion of CA19-9 is 8. 32 ±7. 23U/mL (s ). We have detected 73 serum samples of colorectal cancer, including Duke A phase (5), B phase (29), C phase (30) and D phase (8). Their mean concentration of CA19-9 are 9. 68 ±5. 32U/mL, 12. 87 ±10. 14U/mL, 71. 11 ±90. 53U/mL, and 297. 55 ±255. 11U/mL, resistively. The mean concentration of 60 serum samples of pancreatic cancer is 196. 12 ± 208. 30U/mL. If 30U/mL is used as the cut-off value, the positive rates in colorectal cancer of Duke A, B, C and D phases are 0 %, 13. 8 %, 46. 7 % and 87. 5 %, respectively, and 80 % in pancreatic cancer, while the false positive rate in samples from healthy sabjects is 1. 04%' In this report we also discuss the value of ROC assay in application of CA19-9 IRMA to clinical cancer detection.